ArticleClinical journal of the American Society of Nephrology : CJASN2026
Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-Creatinine Ratio in Asia: Pre-Specified Analysis of CONFIDENCE.
Article in Clinical journal of the American Society of Nephrology : CJASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Effects of finerenone on arterial stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease: a randomised placebo-controlled mechanistic trial (FIVE-STAR).Cardiovascular diabetology · 2025Trial
- Finerenone in Asian patients with diabetic kidney disease: evaluating the evidence for "better efficacy".Clinical kidney journal · 2026Review
- Finerenone in Asian Patients with Type 2 Diabetes Mellitus and Albuminuric Chronic Kidney Disease: From Evidence to Implementation.Diabetes & metabolism journal · 2026Review
- Authors' Reply: Addressing Disparity Efficacy of Finerenone-Empagliflozin Combination in Asian Patients with Diabetic Kidney Disease.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Addressing Disparity: Efficacy of Finerenone-Empagliflozin Combination in Asian Patients with Diabetic Kidney Disease.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Cost-utility analysis of simultaneous initiation of finerenone and empagliflozin for type 2 diabetes mellitus complicated with chronic kidney disease.Frontiers in pharmacology · 2026Article
- Boosting CONFIDENCE in Combination Therapy for Diabetic Kidney Disease in Asia.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.